Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders

E. E. Morgan, S. P. Woods, S. L. Letendre, D. R. Franklin, C. Bloss, A. Goate, R. K. Heaton, A. C. Collier, C. M. Marra, Benjamin Gelman, J. C. McArthur, S. Morgello, D. M. Simpson, J. A. McCutchan, R. J. Ellis, I. Abramson, A. Gamst, C. Fennema-Notestine, D. M. Smith, I. GrantF. Vaida, D. B. Clifford

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

This is a cross-sectional, observational study to evaluate the hypothesis that HIV-seropositive (HIV+) apolipoprotein E4 (APOE4) carriers are at increased risk for HIV-associated neurocognitive disorders (HAND) compared to APOE4 noncarriers with HIV in the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group sample. APOE genotype was determined in 466 CHARTER participants with varying disease stages and histories of antiretroviral treatment who did not have severe psychiatric or medical comorbid conditions that preclude diagnosis of HAND. HAND diagnoses were based on results of comprehensive neurobehavioral evaluation and use of current neuroAIDS diagnostic criteria. HAND status consists of two levels: neuropsychologically normal status (i.e., no HAND) and any HAND diagnosis (i.e., asymptomatic neurocognitive impairment, minor neurocognitive disorder, HIV-associated dementia). Logistic regression analyses revealed no association between APOE4 carrier status and HAND, and there were no interactions between APOE4 carrier status and ethnicity, age, substance use disorders, duration of infection, or nadir CD4. Results did not differ when analysis was restricted to symptomatic HAND, and no APOE4 gene dose-dependent relationship to HAND emerged. APOE4 status was not associated with concurrent HAND in this large, well-characterized sample. This does not preclude emergence of an association between APOE4 status and HAND as this population ages. Prospective, longitudinal studies are needed to examine APOE4 as a risk factor for neurocognitive decline, incident HAND at older ages, and potential associations with cerebrospinal fluid amyloid.

Original languageEnglish (US)
Pages (from-to)150-156
Number of pages7
JournalJournal of NeuroVirology
Volume19
Issue number2
DOIs
StatePublished - Apr 2013

Fingerprint

Apolipoprotein E4
Genotype
HIV
Neurocognitive Disorders
AIDS Dementia Complex

Keywords

  • Genetics
  • HIV/AIDS
  • Neuropsychological assessment

ASJC Scopus subject areas

  • Virology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Neurology

Cite this

Morgan, E. E., Woods, S. P., Letendre, S. L., Franklin, D. R., Bloss, C., Goate, A., ... Clifford, D. B. (2013). Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. Journal of NeuroVirology, 19(2), 150-156. https://doi.org/10.1007/s13365-013-0152-3

Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. / Morgan, E. E.; Woods, S. P.; Letendre, S. L.; Franklin, D. R.; Bloss, C.; Goate, A.; Heaton, R. K.; Collier, A. C.; Marra, C. M.; Gelman, Benjamin; McArthur, J. C.; Morgello, S.; Simpson, D. M.; McCutchan, J. A.; Ellis, R. J.; Abramson, I.; Gamst, A.; Fennema-Notestine, C.; Smith, D. M.; Grant, I.; Vaida, F.; Clifford, D. B.

In: Journal of NeuroVirology, Vol. 19, No. 2, 04.2013, p. 150-156.

Research output: Contribution to journalArticle

Morgan, EE, Woods, SP, Letendre, SL, Franklin, DR, Bloss, C, Goate, A, Heaton, RK, Collier, AC, Marra, CM, Gelman, B, McArthur, JC, Morgello, S, Simpson, DM, McCutchan, JA, Ellis, RJ, Abramson, I, Gamst, A, Fennema-Notestine, C, Smith, DM, Grant, I, Vaida, F & Clifford, DB 2013, 'Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders', Journal of NeuroVirology, vol. 19, no. 2, pp. 150-156. https://doi.org/10.1007/s13365-013-0152-3
Morgan, E. E. ; Woods, S. P. ; Letendre, S. L. ; Franklin, D. R. ; Bloss, C. ; Goate, A. ; Heaton, R. K. ; Collier, A. C. ; Marra, C. M. ; Gelman, Benjamin ; McArthur, J. C. ; Morgello, S. ; Simpson, D. M. ; McCutchan, J. A. ; Ellis, R. J. ; Abramson, I. ; Gamst, A. ; Fennema-Notestine, C. ; Smith, D. M. ; Grant, I. ; Vaida, F. ; Clifford, D. B. / Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. In: Journal of NeuroVirology. 2013 ; Vol. 19, No. 2. pp. 150-156.
@article{010b5f99f396412c8e2a4fc8ea97e3c8,
title = "Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders",
abstract = "This is a cross-sectional, observational study to evaluate the hypothesis that HIV-seropositive (HIV+) apolipoprotein E4 (APOE4) carriers are at increased risk for HIV-associated neurocognitive disorders (HAND) compared to APOE4 noncarriers with HIV in the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group sample. APOE genotype was determined in 466 CHARTER participants with varying disease stages and histories of antiretroviral treatment who did not have severe psychiatric or medical comorbid conditions that preclude diagnosis of HAND. HAND diagnoses were based on results of comprehensive neurobehavioral evaluation and use of current neuroAIDS diagnostic criteria. HAND status consists of two levels: neuropsychologically normal status (i.e., no HAND) and any HAND diagnosis (i.e., asymptomatic neurocognitive impairment, minor neurocognitive disorder, HIV-associated dementia). Logistic regression analyses revealed no association between APOE4 carrier status and HAND, and there were no interactions between APOE4 carrier status and ethnicity, age, substance use disorders, duration of infection, or nadir CD4. Results did not differ when analysis was restricted to symptomatic HAND, and no APOE4 gene dose-dependent relationship to HAND emerged. APOE4 status was not associated with concurrent HAND in this large, well-characterized sample. This does not preclude emergence of an association between APOE4 status and HAND as this population ages. Prospective, longitudinal studies are needed to examine APOE4 as a risk factor for neurocognitive decline, incident HAND at older ages, and potential associations with cerebrospinal fluid amyloid.",
keywords = "Genetics, HIV/AIDS, Neuropsychological assessment",
author = "Morgan, {E. E.} and Woods, {S. P.} and Letendre, {S. L.} and Franklin, {D. R.} and C. Bloss and A. Goate and Heaton, {R. K.} and Collier, {A. C.} and Marra, {C. M.} and Benjamin Gelman and McArthur, {J. C.} and S. Morgello and Simpson, {D. M.} and McCutchan, {J. A.} and Ellis, {R. J.} and I. Abramson and A. Gamst and C. Fennema-Notestine and Smith, {D. M.} and I. Grant and F. Vaida and Clifford, {D. B.}",
year = "2013",
month = "4",
doi = "10.1007/s13365-013-0152-3",
language = "English (US)",
volume = "19",
pages = "150--156",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders

AU - Morgan, E. E.

AU - Woods, S. P.

AU - Letendre, S. L.

AU - Franklin, D. R.

AU - Bloss, C.

AU - Goate, A.

AU - Heaton, R. K.

AU - Collier, A. C.

AU - Marra, C. M.

AU - Gelman, Benjamin

AU - McArthur, J. C.

AU - Morgello, S.

AU - Simpson, D. M.

AU - McCutchan, J. A.

AU - Ellis, R. J.

AU - Abramson, I.

AU - Gamst, A.

AU - Fennema-Notestine, C.

AU - Smith, D. M.

AU - Grant, I.

AU - Vaida, F.

AU - Clifford, D. B.

PY - 2013/4

Y1 - 2013/4

N2 - This is a cross-sectional, observational study to evaluate the hypothesis that HIV-seropositive (HIV+) apolipoprotein E4 (APOE4) carriers are at increased risk for HIV-associated neurocognitive disorders (HAND) compared to APOE4 noncarriers with HIV in the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group sample. APOE genotype was determined in 466 CHARTER participants with varying disease stages and histories of antiretroviral treatment who did not have severe psychiatric or medical comorbid conditions that preclude diagnosis of HAND. HAND diagnoses were based on results of comprehensive neurobehavioral evaluation and use of current neuroAIDS diagnostic criteria. HAND status consists of two levels: neuropsychologically normal status (i.e., no HAND) and any HAND diagnosis (i.e., asymptomatic neurocognitive impairment, minor neurocognitive disorder, HIV-associated dementia). Logistic regression analyses revealed no association between APOE4 carrier status and HAND, and there were no interactions between APOE4 carrier status and ethnicity, age, substance use disorders, duration of infection, or nadir CD4. Results did not differ when analysis was restricted to symptomatic HAND, and no APOE4 gene dose-dependent relationship to HAND emerged. APOE4 status was not associated with concurrent HAND in this large, well-characterized sample. This does not preclude emergence of an association between APOE4 status and HAND as this population ages. Prospective, longitudinal studies are needed to examine APOE4 as a risk factor for neurocognitive decline, incident HAND at older ages, and potential associations with cerebrospinal fluid amyloid.

AB - This is a cross-sectional, observational study to evaluate the hypothesis that HIV-seropositive (HIV+) apolipoprotein E4 (APOE4) carriers are at increased risk for HIV-associated neurocognitive disorders (HAND) compared to APOE4 noncarriers with HIV in the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group sample. APOE genotype was determined in 466 CHARTER participants with varying disease stages and histories of antiretroviral treatment who did not have severe psychiatric or medical comorbid conditions that preclude diagnosis of HAND. HAND diagnoses were based on results of comprehensive neurobehavioral evaluation and use of current neuroAIDS diagnostic criteria. HAND status consists of two levels: neuropsychologically normal status (i.e., no HAND) and any HAND diagnosis (i.e., asymptomatic neurocognitive impairment, minor neurocognitive disorder, HIV-associated dementia). Logistic regression analyses revealed no association between APOE4 carrier status and HAND, and there were no interactions between APOE4 carrier status and ethnicity, age, substance use disorders, duration of infection, or nadir CD4. Results did not differ when analysis was restricted to symptomatic HAND, and no APOE4 gene dose-dependent relationship to HAND emerged. APOE4 status was not associated with concurrent HAND in this large, well-characterized sample. This does not preclude emergence of an association between APOE4 status and HAND as this population ages. Prospective, longitudinal studies are needed to examine APOE4 as a risk factor for neurocognitive decline, incident HAND at older ages, and potential associations with cerebrospinal fluid amyloid.

KW - Genetics

KW - HIV/AIDS

KW - Neuropsychological assessment

UR - http://www.scopus.com/inward/record.url?scp=84882603994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882603994&partnerID=8YFLogxK

U2 - 10.1007/s13365-013-0152-3

DO - 10.1007/s13365-013-0152-3

M3 - Article

C2 - 23408335

AN - SCOPUS:84882603994

VL - 19

SP - 150

EP - 156

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 2

ER -